Peter B Gilbert Selected Research

COVID-19 Vaccines

4/2024	COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials.
7/2023	Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials.
1/2023	Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
4/2022	Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial.
4/2021	Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection.
1/2021	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission.
11/2020	Prospects for a safe COVID-19 vaccine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter B Gilbert Research Topics

Disease

83	Infections 05/2024 - 07/2003
32	COVID-19 04/2024 - 11/2020
25	HIV Infections (HIV Infection) 06/2023 - 09/2003
17	Dengue (Dengue Fever) 10/2023 - 01/2018
9	Acquired Immunodeficiency Syndrome (AIDS) 07/2023 - 12/2002
8	Communicable Diseases (Infectious Diseases) 03/2024 - 05/2010
4	Vaccinia 01/2023 - 11/2014
4	Disease Progression 10/2022 - 09/2005
4	Breakthrough Infections 01/2021 - 09/2004
4	Human Influenza (Influenza) 05/2019 - 01/2007
3	Malaria 05/2024 - 01/2019
3	Viremia 12/2023 - 07/2003
3	Neoplasms (Cancer) 07/2023 - 03/2005
3	Virus Diseases (Viral Diseases) 11/2020 - 11/2013
2	Rabies (Hydrophobia) 05/2024 - 11/2023
2	Vesicular Stomatitis 01/2020 - 11/2017
2	Herpes Zoster 01/2018 - 11/2014
1	Parasitic Diseases (Parasitic Disease) 05/2024
1	Anaphylaxis (Anaphylactic Shock) 03/2024
1	Bacillary Dysentery (Shigellosis) 03/2023
1	Hypoxia (Hypoxemia) 01/2023
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2023
1	Hepatitis C 01/2021
1	Severe Acute Respiratory Syndrome 11/2020
1	Coronavirus Infections 11/2020
1	Persistent Infection 09/2011
1	Colorectal Neoplasms (Colorectal Cancer) 03/2005

Drug/Important Bio-Agent (IBA)

120	VaccinesIBA 05/2024 - 07/2003
26	AIDS VaccinesIBA 07/2023 - 07/2003
23	Biomarkers (Surrogate Marker)IBA 03/2024 - 07/2003
19	Neutralizing AntibodiesIBA 12/2023 - 05/2015
17	AntibodiesIBA 03/2023 - 06/2006
15	Immunoglobulin G (IgG)IBA 03/2023 - 04/2012
13	Dengue VaccinesIBA 10/2023 - 01/2018
11	Proteins (Proteins, Gene)FDA Link 01/2023 - 04/2012
9	Broadly Neutralizing AntibodiesIBA 12/2023 - 09/2011
9	DNA (Deoxyribonucleic Acid)IBA 11/2019 - 05/2006
7	COVID-19 VaccinesIBA 04/2024 - 11/2020
7	2019-nCoV Vaccine mRNA-1273IBA 01/2023 - 08/2021
6	Glycoproteins (Glycoprotein)IBA 09/2019 - 03/2005
5	CYD-TDV vaccineIBA 01/2022 - 01/2018
5	Immunoglobulin A (IgA)IBA 11/2019 - 04/2012
4	Adenosine Monophosphate (AMP)IBA 01/2023 - 01/2017
4	Peptides (Polypeptides)IBA 01/2017 - 11/2006
3	Ad26COVS1IBA 03/2024 - 04/2022
3	Monoclonal AntibodiesIBA 12/2023 - 01/2019
3	EpitopesIBA 10/2022 - 09/2009
3	Immunoglobulins (Immunoglobulin)IBA 12/2021 - 09/2021
3	AIDSVAX B-EIBA 01/2021 - 08/2009
3	AIDSVAXIBA 01/2021 - 04/2013
3	A-Form DNA (A-DNA)IBA 11/2019 - 11/2013
3	AntigensIBA 01/2014 - 03/2005
2	Malaria VaccinesIBA 05/2024 - 11/2023
2	RTS malaria vaccineIBA 05/2024 - 11/2023
2	NVX-CoV2373 adjuvated lipid nanoparticleIBA 10/2023 - 01/2023
2	DNA VaccinesIBA 01/2023 - 11/2017
2	HLA Antigens (Human Leukocyte Antigens)IBA 10/2022 - 01/2022
2	ImmunosorbentsIBA 07/2018 - 01/2018
2	EnzymesIBA 07/2018 - 01/2018
2	Herpes Zoster VaccineIBA 01/2018 - 11/2014
2	Fc Receptors (Fc Receptor)IBA 09/2014 - 05/2007
2	RNA (Ribonucleic Acid)IBA 11/2013 - 09/2005
2	Viral RNAIBA 02/2012 - 08/2009
2	Amino Acids FDA Link 09/2011 - 04/2008
2	Zidovudine (Retrovir)FDA LinkGeneric 08/2006 - 06/2006
1	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 03/2024
1	ChAdOx1 nCoV-19IBA 03/2023
1	LipopolysaccharidesIBA 03/2023
1	casirivimab and imdevimab drug combinationIBA 01/2023
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2023
1	N-acetyltalosaminuronic acid (NAT)IBA 01/2023
1	BNT162 VaccineIBA 01/2021
1	Ebola VaccinesIBA 01/2020
1	IgG Receptors (Fc gamma RI)IBA 11/2019
1	env Gene ProductsIBA 11/2019
1	Influenza Vaccines (Influenza Vaccine)FDA Link 05/2019
1	Neuraminidase (Sialidase)IBA 05/2019
1	CytokinesIBA 01/2019
1	Interleukin-15 (Interleukin 15)IBA 01/2019
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2019
1	ChemokinesIBA 01/2019
1	Combined VaccinesIBA 01/2018
1	MF59 oil emulsionIBA 01/2018
1	Interleukin-12 (IL 12)IBA 11/2017
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2017
1	Recombinant DNA (Recombinant DNA Research)IBA 01/2017
1	GP 140IBA 01/2016
1	Indicators and Reagents (Reagents)IBA 01/2014
1	InterferonsIBA 01/2014
1	HLA-B Antigens (HLA-B)IBA 10/2013
1	ORALIT (ORS)IBA 01/2013
1	SAIDS VaccinesIBA 02/2012
1	Fc gamma receptor IIAIBA 05/2007
1	Nevirapine (Viramune)FDA Link 06/2006
1	Chemokine ReceptorsIBA 04/2006

Therapy/Procedure

5	Therapeutics 01/2021 - 07/2003
2	Art Therapy 01/2022 - 09/2005
1	Intramuscular Injections 01/2018
1	Intravenous Infusions 01/2017
1	Highly Active Antiretroviral Therapy (HAART) 06/2006